Oncologie, a Boston-Shanghai startup, launched operations with $16.5 million in a seed financing led by Pivotal bioVenture Partners China. Oncologie plans to improve cancer care by licensing and partnering innovative combination drugs that improve the efficacy of immune checkpoint inhibitors. It has already made deals for two clinical-stage drug candidates. Oncologie will take advantage of China’s recent regulatory changes by conducting parallel clinical development in China and the US, bringing its IO products to the world’s two largest markets simultaneously.
Source: China Biotoday
